NDC 0781-7238-06 - BUPRENORPHINE AND NALOXONE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0781-7238
- Requested NDC
- 0781-7238-06
- Package NDCs from labels
- 0781-7238-06, 0781-7238-64
- Manufacturer
- Indivior Inc.
- Effective date
- 2021-04-19
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| BUPRENORPHINE AND NALOXONE - Indivior Inc. | Indivior Inc. | 2021-04-19 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-7238-06 | EA - Each | 0781-7238 | d1b5f310-3461-4db8-baf5-71c631018dc9 | 1 | 2019-05-02 |
| 0781-7238-64 | EA - Each | 0781-7238 | 600640b1-4c07-4200-97a8-c84d78c59250 | 1 | 2019-03-12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Henry Schein, Inc. | ddeebc32-9aab-4a2f-8c87-74335d17d5ef | 2026-11-05 | Warnings, Adverse reactions | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Henry Schein, Inc. | d39635a4-ddb3-4d32-8211-eb84c78e9f59 | 2026-11-05 | Warnings, Adverse reactions | F850569PQR |
| naloxone hydrochloride | NALOXONE HYDROCHLORIDE | REMEDYREPACK INC. | 5b13a13f-6ec8-41eb-b216-e43ffd68f01e | 2026-11-02 | Warnings, Adverse reactions | F850569PQR |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | PAI Holdings, LLC dba PAI Pharma | 63201a61-6ac5-41ae-8b2d-ff0d3a8ddfd5 | 2026-10-30 | Adverse reactions | 1Q73Q2JULR |
| pentazocine and naloxone | PENTAZOCINE AND NALOXONE | Sun Pharmaceutical Industries, Inc. | 41ebdaaf-3bbc-419f-b996-0341efc14623 | 2026-10-29 | Boxed warning, Warnings, Adverse reactions | F850569PQR |
| Buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | Gland Pharma Limited | 69ec3405-78ee-4cb4-9180-9bea937a8dcd | 2026-10-16 | Boxed warning, Warnings, Adverse reactions | 56W8MW3EN1 |
| AQUACETIC-30 | CLEANING SOLUTION FOR HEMODIALYSIS MACHINES | Aqua Medica, S.A. de C.V. | 040775ab-41bd-cd36-e063-6394a90a08aa | 2026-10-16 | Warnings | 2968PHW8QP |
| CITRACID-50 | DESINFECTANT SOLUTION FOR HEMODIALYSIS MACHINE | Aqua Medica, S.A. de C.V. | 040713e7-67cd-8eb0-e063-6394a90aa2a9 | 2026-10-16 | Warnings | 2968PHW8QP |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Somerset Therapeutics, LLC | b59ee3cc-9604-4abc-81be-897e2f42aa67 | 2026-10-15 | Warnings, Adverse reactions | F850569PQR |
| Artificial Tears | GLYCERIN | Preferred Pharmaceuticals Inc. | dd646c72-8f47-43c6-a734-db0dcc8cd4d1 | 2026-10-14 | Warnings | 3NXW29V3WO |
| Sal De Uvas Picot | CITRIC ACID MONOHYDRATE, SODIUM BICARBONATE | Navajo Manufacturing Company Inc. | ff6ac79d-564d-4abf-83c7-b01751249c7f | 2026-10-09 | Warnings | 2968PHW8QP |
| Sal de Uvas Picot | CITRIC ACID MONOHYDRATE AND SODIUM BICARBONATE | Navajo Manufacturing Company Inc. | 5d6d297d-770b-dd9f-e063-6294a90a4bb8 | 2026-10-02 | Warnings | 2968PHW8QP |
| REXTOVY | NALOXONE HYDROCHLORIDE | International Medication Systems, Ltd. | fe9735db-c57e-44a8-bffb-b87a84c2a6f3 | 2026-09-30 | Warnings, Adverse reactions | F850569PQR |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Golden State Medical Supply, Inc. | 4f6e0056-b19d-0d0e-e063-6294a90a16e5 | 2026-09-21 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | REMEDYREPACK INC. | 9f7b0a28-f937-4d4d-b793-ca3468bd28e0 | 2026-09-17 | Warnings, Adverse reactions | 56W8MW3EN1 |
| BUPRENORPHINE AND NALOXONE | BUPRENORPHINE AND NALOXONE | Major Pharmaceuticals | c5fbec69-e7de-44a8-b9fa-0378ae61a9fe | 2026-09-02 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Amneal Pharmaceuticals LLC | 8091a73d-9ecd-4578-a57b-5d85a2c5a16a | 2026-08-25 | Warnings | F850569PQR |
| Rohto All-In-One | HYPROMELLOSE, TETRAHYDROZOLINE HYDROCHLORIDE, ZINC SULFATE | The Mentholatum Company | 43e690e4-b381-46e3-838c-33aef5bdadde | 2026-08-20 | Warnings | 3NXW29V3WO |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | REMEDYREPACK INC. | 4124c4ad-ef62-4c95-8e57-0d843862ae71 | 2026-08-17 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | REMEDYREPACK INC. | 43027750-d218-49e5-867f-c941736d2056 | 2026-08-17 | Warnings, Adverse reactions | 56W8MW3EN1 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.